Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tweaks To German Pharma Law Require Firms to Prove Drugs' Value Within a Year

Executive Summary

Last-minute tweaks to Germany's pharmaceutical sector restructuring laws (AMNOG) require drug firms to provide evidence of a product's value within 12 months of launch – or risk having it struck off the reimbursement list.

You may also be interested in...



After Elections, Germany’s Pharma Industry Faces Uncertain Future

German elections have led to the possibility of several coalition government constellations, but none are particularly good for the pharmaceutical industry.

Novo Nordisk Withholding Tresiba From German HTA Process

Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.

German Austerity Measures Continue As Firms Dispute How Much Has Already Been Saved

Despite overall economic growth, the German health ministry refuses to lift the pharmaceutical price freeze or obligatory rebate to health insurers, saying industry is coping well with them; firms say they have already sacrificed more than had initially been asked.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel